Literature DB >> 12148119

Fibrillary glomerulonephritis associated with crescents as a therapeutic challenge.

Cornelia Blume1, Katrin Ivens, Philip May, Udo Helmchen, Peter M Jehle, M Riedel, Frieder Keller, Bernd Grabensee.   

Abstract

Most cases of fibrillary glomerulonephritis (FG) terminate in end-stage renal disease within a few years. We report on two female patients (41 and 50 years old) with the diagnosis of FG associated with crescentic glomerulonephritis, a combination found in 20% to 25% of cases of FG. A broad spectrum of infectious disease and systemic immunologic disorders could be ruled out by specific assays. Both patients had severely impaired renal function, nephrotic syndrome, and hypertension. Based on the biopsy finding with necrotizing FG, treatment was started with corticosteroids and cyclophosphamide. In both patients, renal function recovered markedly within 6 months of treatment, in one case remaining stable for 3.5 years. Whether or not cyclophosphamide treatment changed the course of the FG itself or counteracted the acute crescentic process cannot be determined from these two patients. Based on these promising preliminary findings and the poor prognosis of FG, however, we recommend cyclophosphamide treatment of patients with FG and additional crescentic glomerulonephritis. For a systematic evaluation of the therapeutic options in FG, a multicenter clinical trial should be conducted. Copyright 2002 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12148119     DOI: 10.1053/ajkd.2002.34548

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  3 in total

Review 1.  Fibrillary Glomerulonephritis and DnaJ Homolog Subfamily B Member 9 (DNAJB9).

Authors:  Nattawat Klomjit; Mariam Priya Alexander; Ladan Zand
Journal:  Kidney360       Date:  2020-07-08

2.  Fibrillary glomerulonephritis presenting as crescentic glomerulonephritis.

Authors:  H H Shah; J Thakkar; J M Pullman; A T Mathew
Journal:  Indian J Nephrol       Date:  2017 Mar-Apr

3.  Fibrillary glomerulonephritis with small fibrils in a patient with the antiphospholipid antibody syndrome successfully treated with immunosuppressive therapy.

Authors:  Muhammad M Javaid; Helen Denley; Senyo Tagboto
Journal:  BMC Nephrol       Date:  2007-05-09       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.